PURPOSE: To investigate the feasibility, efficacy, and safety of adding @entity1311 to @entity900 / @entity2879 chemotherapy and concurrent thoracic radiotherapy (TRT) in treatment of @entity5 ( @entity5 ). @entity1 AND METHODS: @entity1 received five courses of chemotherapy ( @entity1311 175 mg/m2 1-hour intravenous [IV] infusion day 1; @entity900 50 mg/m(2) IV day 1; @entity2879 100 mg/m2 IV day 1; oral @entity2879 100 mg bid days 2 to 5) at 3-week intervals. TRT (42 Gy administered in 15 fractions) was administered concurrent with chemotherapy cycle 3. All @entity1 were evaluated before starting TRT and 4 weeks after termination of chemotherapy. @entity1 achieving complete remission (CR) were administered prophylactic cranial irradiation. RESULTS: Thirty-nine @entity1 were included, and the median age was 63 years. The median follow-up was 36 months (range, 19 to 57 months). The overall response rate was 92% (CR, 81%; partial response, 11%), and the median survival was 21 months. The 1- and 2-year disease-specific survival rates were 69% and 37%, respectively. Of 29 CR @entity1 , 83% have relapsed. Brain metastasis was as frequent as local recurrences (42%). Hematologic @entity137 included grade 3 to 4 @entity1431 in 74% of @entity1 and grade 3 @entity882 in 10%. One treatment-related @entity204 occurred as a result of severe @entity1398 and @entity295 . Hematotoxicity caused dose reductions in 31% of courses. One @entity1 had an anaphylactic reaction during the first @entity1311 infusion. @entity1311 -related @entity16 and @entity925 were reversible. Grade 3 @entity2910 was seen in five @entity1 during and shortly after TRT. CONCLUSION: This novel multimodal regimen is effective and well tolerated in @entity1 with @entity5 . It compares favorably with previously published phase II studies.

Multicenter phase II trial of XXXX , @entity900 , and @entity2879 with concurrent radiation for @entity5 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity295 :: ('MESH:D018805', 'Disease') :: ['septicemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['limited-stage small-cell lung cancer', 'LD-SCLC'] @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Paclitaxel'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity925 :: ('MESH:D063806', 'Disease') :: ['myalgia'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']
